RxDoctor Payments Data

Cornelia Gallo

Child & Adolescent Psychiatry · Westport, CTNPI 1023211653

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 26.8% of the total. Among child & adolescent psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,734in general payments, 2019–2025

Across 384 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Tris Pharma Inc$2K
  • Alkermes, Inc.$893
  • Corium, LLC$593
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$342
  • Vanda Pharmaceuticals Inc.$314
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$6,721100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,734 in reported general payments places this provider in the 95th percentile of 71 child & adolescent psychiatry providers in Connecticut.

See all child & adolescent psychiatry providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole37$95,947
VraylarCariprazine Hcl14$18,497
Chlorpromazine Hcl39$11,205
VyvanseLisdexamfetamine Dimesylate14$8,486
Aripiprazole35$4,966
Paliperidone ErPaliperidone29$3,846
Trazodone Hcl34$1,190
Alprazolam ErAlprazolam18$887
Methylphenidate Hcl17$683
Divalproex Sodium19$552
Lurasidone Hcl14$516
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$483
Divalproex Sodium ErDivalproex Sodium29$460
Sertraline Hcl48$433
FenofibrateFenofibrate Nanocrystallized13$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,806$18,49714 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$186$8,48614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 child & adolescent psychiatry providers in Connecticut.

Other child & adolescent psychiatry in Westport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →